1. Home
  2. Our Firm
  3. News
  4. Guggenheim Securities Expands Healthcare Equity Research Team

Our Firm

August 14, 2012

Guggenheim Securities Expands Healthcare Equity Research Team

Guggenheim Partners, LLC (“Guggenheim”), a global diversified financial services firm, today announced two appointments to its Equity Research team. Louise Chen, Managing Director, will cover the specialty pharmaceutical sector, and Bret Holley, Managing Director, will cover the biotechnology sector. Based in New York, both analysts will report to Raymond Katz, Director of Equity Research for Guggenheim Partners.

“We are excited to have two seasoned and talented analysts join our team. Guggenheim’s growing equity research practice is strongly positioned to offer investors and the marketplace timely and informed analysis of the healthcare industry as it undergoes unprecedented change,” said Mr. Katz.

Ms. Chen joins Guggenheim from New York-based firm Auriga USA LLC where she was a Managing Partner and Senior Analyst of Equity Research. At Auriga, Ms. Chen covered small-to-mid cap specialty pharmaceutical companies such as Teva Pharmaceutical Industries, Forest Laboratories and Warner Chilcott. Prior to Auriga, she spent several years at investment bank Canaccord Genuity where she led the coverage of 14 leading specialty pharmaceutical companies. Earlier in her career, Ms. Chen worked as a Vice President of Equity Research at Morgan Stanley and as a business development executive at Dr. Reddy’s Laboratories.

Mr. Holley joins Guggenheim with more than 15 years of experience in the biotechnology sector. He was most recently a Managing Director and Senior Research Analyst at Oppenheimer & Co., formerly CIBC World Markets, where he spent more than a decade leading the coverage of some of the world’s largest biotechnology companies, including Amgen Inc., Celgene Corp., Gilead Sciences and ImmunoGen, Inc. Earlier in his career, Mr. Holley was a bioinformatics application architect at Ingenuity Systems where he developed biotechnology data software and worked with major biotech and pharmaceutical companies.

About Guggenheim Partners
Guggenheim Partners, LLC is a privately held global financial services firm with more than $160 billion in assets under management. The firm provides asset management, investment banking and capital markets services, insurance, institutional finance and investment advisory solutions to institutions, governments and agencies, corporations, investment advisors, family offices and individuals. Guggenheim Partners is headquartered in New York and Chicago and serves clients around the world from more than 25 offices in nine countries. For more information about Guggenheim Partners, visit guggenheimpartners.com.

Media Contacts:

Thomas S. Mulligan
Sitrick And Company
212.573.6100
thomas_mulligan@sitrick.com

Terry Fahn
Sitrick And Company
310.788.2850
terry_fahn@sitrick.com



May 16, 2018

Guggenheim 2Q Fixed-Income Outlook: Preparing for Long-Awaited Choppier Markets

NEW YORK, NY –  Guggenheim Investments, the global asset management and investment advisory business of Guggenheim Partners, today provided its Second Quarter 2018 Fixed-Income Outlook, “Positioned for Choppier Waters.”

Read More

May 11, 2018

Guggenheim Partners Impact Report

The second edition of the impact report highlights our accomplishments in the areas of social impact and sustainable business practices.

Read Report

May 03, 2018

Guggenheim Securities Hires Mandar Vadhavkar to Expand Healthcare Investment Banking Group

Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Mandar Vadhavkar will join the firm as a Senior Managing Director in the firm’s Healthcare investment banking group, with a focus on advising companies in the healthcare services sector.

Read More



© 2018 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.